Considering that treatment with radiotherapy or a CDK4/6 inhibitor can enhance anti-tumor immunity in vitro, we analyzed the impact of new neoadjuvant therapeutic regimen on alternation in biomarker expression in the numbers of TILs before and after the treatment. Here, CDK4 is linked to neoplasm.